VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (7455)	1/13/2000 3:06:00 PM
From: JMarcus	Read Replies (1) of 9719

Chase H&Q analyst names CNCT and GELX as her top picks among microcap biotechs: "SAN FRANCISCO (CBS.MW) -- Although there's been a lot of buzz surrounding the genomics sector of the biotech industry, Chase H&Q analyst Meg Malloy said in an interview there's still value to be had in some of the smaller companies developing products for niche markets. Her picks include Connetics Corp. (CNCT: news, msgs), which makes ConXn, a drug to treat scleroderma . The disease is a connective tissue disorder that can be fatal in its most severe form. She believes the drug is likely to be a key driver of the company's growth. The U.S. market for scleroderma drugs exceeds $500 million, Malloy said. The company also has a growing dermatology business. Malloy said the stock could reach $30 a share in the next year. Another pick is GelTex (GELX: news, msgs). Malloy said the company has a second generation version of its Renagel capsules in the wings as well as several other candidates in the pipeline. Renagel removes excess phosphorous in kidney patients who lack the ability to filter it themselves. The company also has a cholesterol lowering drug, Cholestagel, for those who can't take Lipitor or other statins, the most widely used cholesterol drugs. Malloy said the stock could reach $30 to $35 within 12 months." cbs.marketwatch.com Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next